Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ACTRN12626000403336) titled 'A Study to Evaluate the Safety, Tolerability and Efficacy of IMD303 in Participants With Advanced Malignant Solid Tumors' on April 1.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Type of endpoint: Safety/efficacy
Primary Sponsor: Catalysis Therapeutics Pty Ltd/Affinity (Chengdu) Pharmaceutical Co., Ltd
Condition:
Advanced Malignant Solid Tumors
Advanced Malignant Solid Tumors
Cancer - Malignant melanoma
Intervention:
This is a dose-escalation study evaluating IMD303 in participants with advanced malignant solid tumors. IMD...